Last reviewed · How we verify
Dolutegravir, Elvitegravir and Cobicistat
Dolutegravir, Elvitegravir and Cobicistat is a Small molecule drug developed by St Stephens Aids Trust. It is currently in Phase 1 development.
At a glance
| Generic name | Dolutegravir, Elvitegravir and Cobicistat |
|---|---|
| Sponsor | St Stephens Aids Trust |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (PHASE4)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dolutegravir, Elvitegravir and Cobicistat CI brief — competitive landscape report
- Dolutegravir, Elvitegravir and Cobicistat updates RSS · CI watch RSS
- St Stephens Aids Trust portfolio CI
Frequently asked questions about Dolutegravir, Elvitegravir and Cobicistat
What is Dolutegravir, Elvitegravir and Cobicistat?
Dolutegravir, Elvitegravir and Cobicistat is a Small molecule drug developed by St Stephens Aids Trust.
Who makes Dolutegravir, Elvitegravir and Cobicistat?
Dolutegravir, Elvitegravir and Cobicistat is developed by St Stephens Aids Trust (see full St Stephens Aids Trust pipeline at /company/st-stephens-aids-trust).
What development phase is Dolutegravir, Elvitegravir and Cobicistat in?
Dolutegravir, Elvitegravir and Cobicistat is in Phase 1.
Related
- Manufacturer: St Stephens Aids Trust — full pipeline